Nov 8, 2013 by Dave WilliamsonBreaking Down Endo Health's Brilliant BuyoutHere's why the market loved this creative acquisition.
Nov 8, 2013 by Dave Williamson and Alison SouthwickKey Takeaways From Vivus' Bad QuarterHere's why the market gutted Vivus after its earnings report.
Oct 29, 2013 by Dave WilliamsonRevelations From Obamacare Failure HearingsObamacare contractors CGI Group, Experian, and UnitedHealth subsidiary Quality Systems point fingers at one another and the CMS in front of Congress.
Oct 20, 2013 by Dave WilliamsonThe Simple Feature That Could Save ObamacareWhy Washington, D.C., needs to copy Washington state's insurance exchange.
Oct 14, 2013 by Dave WilliamsonNo Easy Fixes for Obamacare GlitchesAetna's CEO has concerns over Obamacare exchange functionality and scalability.
Oct 11, 2013 by Dave Williamson and Max MacalusoHow the FDA Ruined Amarin's DayIs Amarin getting set up for an FDA approval or firing squad?
Oct 9, 2013 by Dave Williamson and Max MacalusoAriad's 66% Collapse: Safety Trumps AllAriad Pharmaceuticals plunges 66% on safety concerns for its key rug Iclusig.
Oct 9, 2013 by Dave Williamson and Max MacalusoBloodbath Signals Biotech Bubble Bursting?It's another sharp sell-off for biotech stocks.
Oct 8, 2013 by Dave WilliamsonDebt Ceiling Fears Spark Biotech InfernoBiotech stocks had a record sell-off as the debt ceiling deadline approaches.
Oct 4, 2013 by Dave WilliamsonBiotech Buyout Celebration or Raw Deal?Will Sarissa Capital be able to stop biotech Astex Pharmaceuticals from being acquired by Otsuka?
Oct 1, 2013 by Dave Williamson and Max MacalusoPrivate Equity's Newest Target: J&J?Private equity firms are rumored to be circling around Johnson & Johnson's diagnostics business.
Oct 1, 2013 by Dave Williamson and Max Macaluso1 Biotech Stock's Disruptive Diabetes DrugLexicon shares pop 21% after good news on its diabetes drug candidate
Oct 1, 2013 by Dave Williamson and Max MacalusoObamacare: Glitches Gone Wild or Wild Success?The Affordable Care Act's state-based insurance exchanges go live.
Sep 30, 2013 by Dave Williamson and Max MacalusoIs Achillion a Bad News Buy Post-Bloodbath?Shares were cut in half after its hepatitis C drug continues on clinical hold.
Sep 30, 2013 by Dave Williamson and Max MacalusoGovernment Shutdown Looms Over Obamacare's DebutWill the health law's October 1 debut be affected by a government shutdown?
Sep 30, 2013 by Dave Williamson3 Important Exchange Insights on Obamacare EveDelays and glitches may ruin the Affordable Care Act's big day.
Sep 29, 2013 by Dave Williamson and Max MacalusoObamacare Rate Shock: All Hype?Discussion over the insurance exchanges and and the announced premium prices.
Sep 27, 2013 by Dave Williamson and Max MacalusoMounting Evidence of Obamacare's Unintended ConsequencesTaking a closer look at the changing dynamics of company-offered health care.
Sep 26, 2013 by Dave WilliamsonAnother Major Pipeline Setback for Eli LillyWhy these mixed-bag results for ramucirumab were more dad than good.
Sep 26, 2013 by Dave Williamson and Max MacalusoThe Next Great Cosmetic Drug?Will fewer chins equal more profits for Kythera?
